Assessing the Readability of Patient-Reported Outcome Measures in Trials for Drugs with Recent FDA Approval

Author(s)

Ruzich E1, Meyers O2
1IQVIA, Cambridge, MA, USA, 2IQVIA, Beachwood, OH, USA

OBJECTIVES: When using patient-reported outcome (PRO) measures, the language must be understood by patients. This can be tested empirically with qualitative studies and can also be measured by evaluating readability. Readability, the ability of an individual to understand written text, can be measured using a variety of standard indices. However, evidence suggests that measurement and reporting of readability metrics is not standard practice in PRO measure development.

METHODS: This study evaluated the readability of PRO measures from FDA submissions for products approved fourth quarter, 2020. PROs were included that were listed in the approved labeling or medical review, as presented on the Drugs@FDA database. Supplemental information about the outcomes measured in pivotal trials was extracted from clinicaltrials.gov.

Selected PROs were processed by editing the text to remove headings, footers, and response options and combining item stems and questions to form complete sentences. Microsoft Word was used to calculate Flesch Reading Ease (range 0-100, higher scores indicate greater readability; 60-70 is considered “plain English”) and Flesch-Kincaid Grade Level (based on US educational levels, average American scores between 7th and 8th grade).

RESULTS: Thirteen products received FDA approval during 4Q2020. Specific information on PRO measures was provided for 4 products, with 12 PROs; 11 PROs were readily available and included in the analysis Flesch Reading Ease averaged 69.4 (range: 52.0, 90.3) and Flesch-Kincaid Grade Level averaged 6.98 (range: 3.4, 10.4). Although no consensus exists for acceptable readability, many view 6th grade as an appropriate maximum level, or reading ease score of 60-70.

CONCLUSIONS: Present results indicate that, although PROs included in FDA submissions are acceptable on average, there is substantial variability. Some PROs may present a challenge to the average reader. Further work is needed on the most appropriate methods for developing readable PRO measures and for assessing readability of existing measures.

Conference/Value in Health Info

2021-05, ISPOR 2021, Montreal, Canada

Value in Health, Volume 24, Issue 5, S1 (May 2021)

Code

PMU60

Topic

Clinical Outcomes, Health Policy & Regulatory, Patient-Centered Research

Topic Subcategory

Approval & Labeling, Clinical Outcomes Assessment, Patient Engagement, Patient-reported Outcomes & Quality of Life Outcomes

Disease

Drugs, No Specific Disease

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×